EU Trials Register Now Holds Data on Over 50k Studies
Information about more than 50,000 clinical trials is now available on the European Union (EU) Clinical Trials Register.
The register contains data on 31,456 current trials with a EudraCT protocol, of which 5,048 are clinical trials conducted on subjects of less than 18 years of age. It also presents details about 18,700 older pediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
The register, which covers studies that started after May 1, 2004 allows users to search for protocol and results information on both interventional clinical trials that are conducted in the EU and the European Economic Area (EEA), as well as clinical trials conducted outside the EU/EEA that are linked to European pediatric medicine development.
It also maintains a list of patient/consumer organizations who may be able provide information on clinical trials within various disease areas. These are organizations that regularly work with the European Medicines Agency.
For more information about the initiative, click here.
Philip Ward is the European Editor for Applied Clinical Trials.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.
